Megasoft [MEGASOFT] vs Kilitch Drugs [KILITCH] Detailed Stock Comparison

Megasoft

NSE
Loading...

Kilitch Drugs

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Megasoft wins in 10 metrics, Kilitch Drugs wins in 8 metrics, with 0 ties. Megasoft appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricMegasoftKilitch DrugsBetter
P/E Ratio (TTM)6.7920.99Megasoft
Price-to-Book Ratio7.582.88Kilitch Drugs
Debt-to-Equity Ratio96.5524.66Kilitch Drugs
PEG Ratio-0.010.17Megasoft
EV/EBITDA7.9416.91Megasoft
Profit Margin (TTM)69.03%13.65%Megasoft
Operating Margin (TTM)90.92%5.61%Megasoft
EBITDA Margin (TTM)90.92%5.61%Megasoft
Return on Equity-20.84%13.32%Kilitch Drugs
Return on Assets (TTM)-8.22%8.54%Kilitch Drugs
Free Cash Flow (TTM)$194.75M$-293.31MMegasoft
1-Year Return139.49%0.61%Megasoft
Price-to-Sales Ratio (TTM)6.173.08Kilitch Drugs
Enterprise Value$12.26B$5.62BMegasoft
EV/Revenue Ratio6.882.70Kilitch Drugs
Gross Profit Margin (TTM)N/A40.98%N/A
Revenue per Share (TTM)$24$129Kilitch Drugs
Earnings per Share (Diluted)$21.89$17.26Megasoft
Beta (Stock Volatility)1.05-0.19Kilitch Drugs
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Megasoft vs Kilitch Drugs Stock Performance Analysis

Loading Price Chart...

Megasoft
Kilitch Drugs
Megasoft Stock Overview | Kilitch Drugs Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Megasoft3.41%7.28%23.83%83.23%210.11%86.75%
Kilitch Drugs-0.47%-1.18%-12.75%-17.34%-2.73%7.80%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Megasoft139.49%341.23%2,136.19%3,324.17%375.72%14.18%
Kilitch Drugs0.61%113.61%325.92%915.71%172.90%172.90%

News Based Sentiment: Megasoft vs Kilitch Drugs

Megasoft

News based Sentiment: POSITIVE

Megasoft demonstrated a significant financial turnaround in September, moving from losses to profits and receiving a 'Strong Buy' recommendation from analysts. While some price volatility occurred, the overall trend is positive, indicating a potential shift in the company's fortunes and making it a noteworthy month for investors.

View Megasoft News Sentiment Analysis

Kilitch Drugs

News based Sentiment: MIXED

September brought a blend of positive and negative developments for Kilitch Drugs. While annual growth remains strong and the company is profitable, a quarterly revenue decline, a valuation downgrade, and a shift to a mildly bearish technical trend create a mixed investment picture. Investors need to carefully weigh these factors.

View Kilitch Drugs News Sentiment Analysis

Performance & Financial Health Analysis: Megasoft vs Kilitch Drugs

MetricMEGASOFTKILITCH
Market Information
Market Cap i₹11.08B₹6.39B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i190,59714,592
90 Day Avg. Volume i203,87611,254
Last Close₹169.96₹350.80
52 Week Range₹49.06 - ₹172.57₹299.95 - ₹500.00
% from 52W High-1.51%-29.84%
All-Time High₹172.57 (Sep 23, 2025)₹500.00 (Jul 15, 2025)
% from All-Time High-1.51%-29.84%
Growth Metrics
Quarterly Revenue GrowthN/A0.29%
Quarterly Earnings GrowthN/A1.26%
Financial Health
Profit Margin (TTM) i0.69%0.14%
Operating Margin (TTM) i0.91%0.06%
Return on Equity (TTM) i-0.21%0.13%
Debt to Equity (MRQ) i96.5524.66
Cash & Liquidity
Book Value per Share (MRQ)₹19.63₹125.88
Cash per Share (MRQ)₹1.29₹36.88
Operating Cash Flow (TTM) i₹-492,054,000₹8.18M
Levered Free Cash Flow (TTM) i₹-299,374,000₹267.01M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend i₹0.00₹0.00

Valuation & Enterprise Metrics Analysis: Megasoft vs Kilitch Drugs

MetricMEGASOFTKILITCH
Price Ratios
P/E Ratio (TTM) i6.7920.99
Forward P/E iN/A23.68
PEG Ratio i-0.010.17
Price to Sales (TTM) i6.173.08
Price to Book (MRQ) i7.582.88
Market Capitalization
Market Capitalization i₹11.08B₹6.39B
Enterprise Value i₹12.26B₹5.62B
Enterprise Value Metrics
Enterprise to Revenue i6.882.70
Enterprise to EBITDA i7.9416.91
Risk & Other Metrics
Beta i1.05-0.19
Book Value per Share (MRQ) i₹19.63₹125.88

Financial Statements Comparison: Megasoft vs Kilitch Drugs

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)MEGASOFTKILITCH
Revenue/Sales i₹0₹431.40M
Cost of Goods Sold i₹0₹254.62M
Gross Profit i₹0₹176.78M
Research & Development iN/AN/A
Operating Income (EBIT) i₹-168.12M₹24.21M
EBITDA i₹-131.33M₹58.22M
Pre-Tax Income i₹1.67B₹34.49M
Income Tax i₹310.00M₹11.87M
Net Income (Profit) i₹1.36B₹22.63M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)MEGASOFTKILITCH
Cash & Equivalents i₹91.70M₹97.49M
Total Current Assets i₹560.34M₹1.74B
Total Current Liabilities i₹683.12M₹843.10M
Long-Term Debt i₹1.30B₹277.70M
Total Shareholders Equity i₹1.44B₹2.00B
Retained Earnings i₹348.54M₹1.11B
Property, Plant & Equipment i₹2.00B₹41.13M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)MEGASOFTKILITCH
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricMEGASOFTKILITCH
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i190,59714,592
Average Daily Volume (90 Day) i203,87611,254
Shares Outstanding i73.77M16.43M
Float Shares i42.39M4.00M
% Held by Insiders i0.41%0.69%
% Held by Institutions i0.00%0.00%

Dividend Analysis & Yield Comparison: Megasoft vs Kilitch Drugs

MetricMEGASOFTKILITCH
Last 12-Month Dividend i₹0.00₹0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend i₹0.00₹0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends i₹0.00₹0.00
Ex-Dividend DateN/AN/A